Dolcanatide 是一种具有口服活性的GC-C(鸟苷酸环化酶-C) 激动剂。Dolcanatide 具有通便、抗痛和抗炎的活性，可用于炎症性肠病的研究。
| 生物活性 | Dolcanatide is an orally activeGC-C(guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research[1][2]. |
体外研究
(In Vitro) | Dolcanatide (0-10 μM; 30 min) activates GC-C receptors to stimulate cGMP synthesis in a dose-dependent manner in T84 cells[2].
Dolcanatide (1 μM; 16 h) suppresses lipopolysaccharide-induced paracellular permeability in Caco-2 and T84 cells[1].
Cell Viability Assay[2] | Cell Line: | T84 cells | | Concentration: | 0-10 μM | | Incubation Time: | 30 min | | Result: | Showed EC50value of 0.28 μM. |
|
体内研究
(In Vivo) | Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates TNBS-induced rectal allodynia in rats[1].
Dolcanatide (oral administration; 0.01 and 0.05 mg/kg; once) alleviates stress-induced colorectal hypersensitivity (CRD) in rats[1].
| Animal Model: | TNBS-induced rectal allodynia in rats[1] | | Dosage: | 0.01 and 0.05 mg/kg | | Administration: | Oral administration; 0.01 and 0.05 mg/kg; once | | Result: | Attenuated the TNBS-induced increase in the number of abdominal contractions (distending pressures up to 60 mmHg). |
| Animal Model: | Stress-induced visceral hypersensitivity in Wistar rats[1] | | Dosage: | 0.01 and 0.05 mg/kg | | Administration: | Oral administration; 0.01 and 0.05 mg/kg; once | | Result: | Resulted in a significant reduction in the rate of PRS (partial restraint stress)-induced abdominal contractions with increasing CRD (colorectal distension) pressures. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com